Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 2/20 | 1.00 |
| ▸ | PDE9A | O76083 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3496118 | 1.00 | PDE5A (1.00) | PDE5APDE9AMEN1CYP1A2KMT2A | |
| SCHEMBL13503511 | 0.83 | PDE5A (0.71) | PDE5APDE9AMEN1CYP1A2KMT2A | |
| SCHEMBL3590957 | 0.83 | PDE5A (0.71) | PDE5APDE9AMEN1CYP1A2KMT2A | |
| SCHEMBL3590956 | 0.83 | PDE5A (0.71) | PDE5APDE9AMEN1CYP1A2KMT2A | |
| SCHEMBL3586072 | 0.83 | PDE5A (0.71) | PDE5APDE9AMEN1CYP1A2KMT2A | |
| SCHEMBL13341429 | 0.83 | PDE9A (0.71) | PDE5APDE9AMEN1CYP1A2KMT2A | |
| SCHEMBL3586067 | 0.83 | PDE5A (0.71) | PDE5APDE9AMEN1CYP1A2KMT2A | |
| SCHEMBL3597802 | 0.80 | PDE5A (0.66) | PDE5APDE9AMEN1CYP1A2KMT2A | |
| SCHEMBL3597805 | 0.80 | PDE5A (0.66) | PDE5APDE9AMEN1CYP1A2KMT2A | |
| SCHEMBL16226933 | 0.80 | PDE9A (0.66) | PDE5APDE9AMEN1CYP1A2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2848620-B1 | QUINOXALINE DERIVATIVES | ASKA PHARM CO LTD (JP) | 2016-09-28 | — | — | EP | claimed |
| US-9040536-B2 | Substituted pyrrolo[1,2-a]quinoxalines as PDE9 inhibitors | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2015-05-26 | — | — | US | claimed |
| US-20140336197-A1 | SUBSTITUTED IMIDAZO [1,5-a]QUINOXALINES AS A PDE9 INHIBITOR | ASKA PHARM CO LTD (JP) | 2014-11-13 | — | — | US | claimed |
| EP-2848620-B1 | QUINOXALINE DERIVATIVES | ASKA PHARM CO LTD (JP) | 2016-09-28 | — | — | EP | disclosed |
| EP-2848620-B1 | QUINOXALINE DERIVATIVES | ASKA PHARM CO LTD (JP) | 2016-09-28 | — | — | EP | disclosed |
| US-9040536-B2 | Substituted pyrrolo[1,2-a]quinoxalines as PDE9 inhibitors | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2015-05-26 | — | — | US | disclosed |
| US-9040536-B2 | Substituted pyrrolo[1,2-a]quinoxalines as PDE9 inhibitors | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2015-05-26 | — | — | US | disclosed |
| US-9040536-B2 | Substituted pyrrolo[1,2-a]quinoxalines as PDE9 inhibitors | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2015-05-26 | — | — | US | disclosed |
| EP-2489667-B1 | Quinoxaline derivative | ASKA PHARM CO LTD (JP) | 2015-04-15 | — | — | EP | disclosed |
| EP-2848620-A1 | Quinoxaline derivatives | ASKA Pharmaceutical Co., Ltd. (JP) | 2015-03-18 | — | — | EP | disclosed |
| EP-2848620-A1 | Quinoxaline derivatives | ASKA Pharmaceutical Co., Ltd. (JP) | 2015-03-18 | — | — | EP | disclosed |
| US-20100113484-A1 | TREATING AGENT OF UROPATHY | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-05-06 | — | — | US | disclosed |
| US-20100113484-A1 | TREATING AGENT OF UROPATHY | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-05-06 | — | — | US | disclosed |
| US-20100113484-A1 | TREATING AGENT OF UROPATHY | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-05-06 | — | — | US | disclosed |
| US-20100048556-A1 | QUINOXALINE DERIVATIVES | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-02-25 | — | — | US | disclosed |
| US-20100048556-A1 | QUINOXALINE DERIVATIVES | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-02-25 | — | — | US | disclosed |
| US-20100048556-A1 | QUINOXALINE DERIVATIVES | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-02-25 | — | — | US | disclosed |
| EP-2123301-A1 | THERAPEUTIC AGENT FOR URINARY TRACT DISEASE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-11-25 | — | — | EP | disclosed |
| EP-2123301-A1 | THERAPEUTIC AGENT FOR URINARY TRACT DISEASE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-11-25 | — | — | EP | disclosed |
| EP-2103613-A1 | QUINOXALINE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048556-A1 | QUINOXALINE DERIVATIVES | PDE9A, ADCY9, PRMT9 | PDE5A 8/4885PDE9A 1/4885MEN1 4034/4885 |
| US-20140336197-A1 | SUBSTITUTED IMIDAZO [1,5-a]QUINOXALINES AS A PDE9 INHIBITOR | PDE9A, ADCY9, PDE3A | PDE5A 6/4885PDE9A 1/4885MEN1 4005/4885 |
| US-20100113484-A1 | TREATING AGENT OF UROPATHY | BPHL, PDE12, UROD | PDE5A 14/4885PDE9A 6/4885MEN1 3598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.